NASDAQ:GALT - Galectin Therapeutics, Inc.
$3.94
 $-0.06
-1.50%
12:50PM EDT
2019-07-22
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GALT     avg for
industry  
  avg for
sector  
42 stocks weight:  4. 95   217. 37   399. 45  
42 stocks rank:  4. 23 K 1. 27 K 716. 99  
# analyst opinions:  2. 00   13. 21   13. 71  
mean recommendation:  2. 00   2. 10   2. 04  

quick ratio:  7. 69   5. 49   1. 88  
current ratio:  8. 25   5. 87   2. 36  

target price low:  11. 00   83. 44   114. 90  
target price avg:  11. 00   106. 20   137. 90  
target price high:  11. 00   132. 30   158. 97  
1-yr high:  6. 93   111. 86   142. 57  
last close:  4. 00   86. 79   125. 44  
50-day avg:  4. 07   86. 68   122. 63  
200-day avg:  4. 58   89. 22   121. 38  
1-yr low:  3. 43   69. 78   100. 51  
volume:  206. 78 K 2. 62 M 3. 43 M
50-day avg volume:  356. 07 K 3. 20 M 4. 16 M
200-day avg volume:  348. 38 K 2. 99 M 4. 75 M

1-day return:  2. 30 % -1. 30 % -0. 99 %
this week return:  2. 04 % 0. 45 % -0. 20 %
12-wk return:  -18. 03 % 0. 94 % 4. 84 %
52-wk return:  -31. 28 % -1. 30 % 10. 55 %

enterprise value (EV):  177. 78 M 45. 10 B 122. 38 B
market cap:  223. 98 M 38. 96 B 108. 40 B
total debt:  115. 00 K 10. 90 B 17. 48 B
debt/equity:  1. 68   57. 18   120. 05  
net income (common):  -19. 60 M 2. 07 B 4. 05 B

shares outstanding:  37. 57 M 538. 09 M 1. 24 B
shares:  32. 88 M 548. 00 M 1. 22 B
shares short:  3. 80 M 10. 98 M 11. 87 M
shares short prior month:  4. 06 M 9. 32 M 12. 05 M
short ratio:  8. 62   5. 60   3. 34  
short % of float:  9. 34 % 6. 48 % 2. 64 %
total cash/share:  0. 15   10. 98   9. 19  
total cash:  6. 97 M 5. 93 B 6. 10 B
free cash flow:  -5. 09 M 2. 92 B 4. 55 B
operating cash flow:  -9. 95 M 3. 80 B 5. 78 B

book value:  0. 10   13. 35   27. 45  
price/book:  40. 00   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 47   2. 10   4. 23  
forward EPS:  -0. 53   3. 45   7. 10  
P/E:  -8. 44   1. 90   32. 10  
forward P/E:  -7. 55   6. 46   15. 47  
PE/G:  1. 30   0. 70   -0. 54  
growth:  -6. 51 % 265. 63 % 79. 11 %
earnings high:  -0. 06   0. 89   1. 68  
earnings avg:  -0. 12   0. 70   1. 57  
earnings low:  -0. 18   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -115. 50 % -2. 34 % 5. 28 %
return on equity:  -253. 26 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  1. 45   1. 27   0. 91  
sharpe (1yr):  -0. 08   0. 16   0. 77  

held % insiders:  24. 55 % 6. 06 % 3. 29 %
held % institutions:  12. 63 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : GALT
.    101.555 =       101.555 :: --> INITIAL WEIGHT <--
.    - 0.474 =       101.081 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.     x 2.22 =       224.355 :: P/E factor
.    x 0.977 =        219.22 :: PE/G factor
.    x 1.652 =       362.051 :: beta factor
.    x 0.665 =       240.732 :: sharpe factor
.    x 2.594 =       624.475 :: current ratio factor
.    x 1.072 =       669.543 :: quick ratio factor
.    x 1.056 =       707.314 :: short ratio factor
.    x 1.253 =       886.382 :: price-to-book factor
.    x 1.015 =       899.316 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      1907.264 :: sector+industry 1-year gains factor
.    x 1.009 =      1925.246 :: industry 12-weeks return factor
.    x 1.308 =      2518.007 :: industry 2-weeks return factor
.    x 0.999 =      2514.772 :: "drift" penalty 5 days ago
.     / 1.99 =      1263.898 :: overall "drift" factor
.    x 0.938 =      1185.109 :: largest single-day jump factor
.    x 0.076 =        89.917 :: low price factor
.    x 0.286 =        25.704 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.281 =          7.22 :: forward EPS factor
.    x 0.739 =         5.334 :: forward P/E factor
.    x 1.185 =         6.319 :: industry recommendation factor
.    x 2.098 =        13.258 :: company recommendation factor
.    x 1.003 =        13.294 :: factor historical industry gain for week 29
.   x 11.509 =       153.005 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         3.517 :: reduced for readability
.     + 1.43 =         4.947 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      4.947 :: FINAL WEIGHT for NASDAQ:GALT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org